However, the CRC TME—especially in microsatellite stable (MSS) and consensus molecular subtype 4 (CMS4) tumors—is characterized by immunosuppressive factors such as TGF-β and PD-L1, which impair NK cell function and facilitate tumor progression. Here, TGFB1 is linked to neoplasm.